Navigation Links
Esperance Pharmaceuticals Completes $7.5 Million Series B Financing
Date:6/1/2011

ion."

Esperance is using its CLYP™ technology to develop a robust portfolio of novel targeted membrane-disrupting peptides (tMDPs) to selectively destroy cancer cells that express target receptors. EP-100, the lead candidate, is designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces and is currently in a Phase 1 study in patients with advanced solid tumors. LHRH receptors are over-expressed in a wide range of human cancers including breast, prostate, endometrial, pancreatic, ovarian, skin, testicular and blood cancers. In addition to EP-100, Esperance has other drug candidates in preclinical stages of development, all of which have a unique targeting mechanism of action whereby candidates bind specifically and exclusively to surface antigens or receptors on cancer cells.

About Esperance Pharmaceuticals

Esperance Pharmaceuticals, Inc. is a clinical stage company developing a new class of targeted anticancer drugs using its Cationic Lytic Peptide (CLYP™) platform technology. These drug candidates, called targeted membrane-disrupting peptides (tMDPs) and antibody drug conjugates (ADCs) selectively seek and destroy cancer cells, including cells known to be resistant to chemotherapeutic drugs, without harming normal cells. Targeting occurs through binding to specific receptors and antigens on the cell's surface. The Company was founded on patented technology discovered by scientists at the Pennington Biomedical Research Center, the Louisiana State (LSU) Ag Center and LSU main campus. Founding investors include the Louisiana Fund I, Themelios Ventures and Research Corporation Technologies. Additional investors include Sanofi, Advantage Capital Partners/Louisiana Technology Fund and private investors. More information can be found at www.esperancepharma.com.


'/>"/>
SOURCE Esperance Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Regen BioPharma, Inc. (OTCBB: RGBP) and ... means of delivering its patented (US Patent 8,263,571) ... utilizing a clinically approved formulation as delivery system.  ... gene silencing therapeutics in which the gene silencing ... body.  By utilizing a local delivery system, potential ...
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. , ... SNY ; EURONEXT: SAN) and the life sciences team ... improve care and outcomes for people with type 1 ... diabetes treatments and devices with Google,s expertise in analytics, ... will explore how to improve diabetes care by developing ...
(Date:8/31/2015)... 31, 2015  Qualcomm Incorporated (NASDAQ: QCOM ... Life, Inc., is collaborating with Davita Healthcare ... solutions powered by Qualcomm Life,s 2net™ Device Connectivity ... continuous care, informed interventions and better management of ... Life,s annual Connect 2015 ecosystem conference ...
Breaking Medicine Technology:Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
... (NYSE: CFN ), a leading, global medical ... to sell its OnSite Services instrument management and ... were not disclosed. (Logo:   http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO ) ... with our strategy to optimize our portfolio of businesses as ...
... 11, 2011 Reportlinker.com announces that a new ... Advanced Drug Delivery Markets (Liposomes, ... http://www.reportlinker.com/p0358466/Advanced-Drug-Delivery-Markets-Liposomes-Polymers-and-Monoclonal-Antibodies.html Drug delivery is evolving ... formulations being discovered frequently. Advanced drug delivery deals ...
Cached Medicine Technology:CareFusion Announces Sale of OnSite Services Instrument Management and Repair Business 2CareFusion Announces Sale of OnSite Services Instrument Management and Repair Business 3Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) 2Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) 3
(Date:9/1/2015)... OH (PRWEB) , ... September 01, 2015 , ... Mercy ... – has devoted the 10th of its monthly Mercy Health: Helping You Be Well ... affecting one in seven men. , In a concise video on Mercy Health’s ...
(Date:9/1/2015)... ... September 01, 2015 , ... Ogawa’s new massage chairs tout ... more effective and humanlike than ever before. With the goal of bringing wellness to ... the Ogawa Active SuperTrac. , As in its name, the Ogawa Refresh ...
(Date:9/1/2015)... Miramar Beach, FL (PRWEB) , ... September 01, ... ... free pharmacy discount cards, launched its consumer-friendly, informational video this week to coincide ... country: http://www.USAMedicalCard.com/video . , According to the CDC, elementary school children ...
(Date:9/1/2015)... ... September 01, 2015 , ... Éminence Organic ... products, the VitaSkin™ Exfoliating Peels. This revolutionary collection of natural peel solutions complements ... and Clear. , Formulated with alpha hydroxy acids and natural active ingredients, ...
(Date:9/1/2015)... ... September 01, 2015 , ... Dr. Trace Curry successfully placed one of the ... the last month the FDA has approved two intra-gastric balloons, the ORBERA ™ ... the first incisionless, reversible, weight loss procedures available to Americans. , Dr. ...
Breaking Medicine News(10 mins):Health News:New Mercy Health Video Explains Most-Common Cancer Found in Men 2Health News:Ogawa World USA Releases New Massage Chairs to the US 2Health News:Ogawa World USA Releases New Massage Chairs to the US 3Health News:USA Medical Card Launches New FAQ Video During Back-to-School 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 3Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2
... The scoring system government agencies use to rate ... because they do not take into account the degree ... facilities include a specialized dementia unit according to a ... from Indiana University School of Medicine and the Regenstrief ...
... the University of Michigan Medical School and MedImmune, the ... agreement to work together on a broad range of ... from one of the nation,s top medical research institutions ... developers of biologic therapies. UMMS and MedImmune ...
... viewpoint of the severity of irritable bowel syndrome (IBS) ... of IBS but broader psychological problems, according to a ... the official journal of the American Gastroenterological Association. ... cost-effective manner within tight time constraints and at a ...
... Swedish medical university Karolinska Institutet have developed a new ... kinds of RNA and DNA molecules is a fundamental ... transfer the genetic information in cells. Thus, improved measurement ... cells. It is very difficult to detect small ...
... News) -- Holiday foods and feasts can cause trouble ... disease (GERD), but there are things they can do ... occurs when a faulty valve between the stomach and ... esophagus. Symptoms of GERD include heartburn, acid regurgitation, wheezing, ...
... Nov. 21 (HealthDay News) -- A hand hygiene and cough ... and the number of absences, a new study says. ... program and five schools that received no special hygiene training. ... Flu" program were: , Wash or sanitize your hands ...
Cached Medicine News:Health News:Nursing home quality scorecards don't tell the whole score 2Health News:U-M Medical School and MedImmune join forces to accelerate search for new therapies 2Health News:Psychological factors affect IBS patients' interpretation of symptom severity 2Health News:A better way to count molecules discovered 2Health News:Holiday Foods May Trigger GERD Symptoms 2Health News:School Hygiene Program Reduced Flu Cases 2
High speed, programmable refrigerated centrifuge. High efficiency separations, "Like clockwork" accuracy, aerosol containment, Accommodating, Re-Run control, Glove-Friendly membrane, centrifuge statu...
... 460 family of centrifuges ... that meets a wide ... feature high capacity, versatility ... technology and high safety ...
The Quantum performs centrifugal blood cell separations, urine separations, and sperm cell washing. 24 place angle head, variable speed, and automatic braking system, calibrated variable speed....
... centrifuge is designed especially for ... cover with safety interlock switch, ... emissions, "hold" position for continuous ... motor, maximum stability and compact, ...
Medicine Products: